Clinical Trials Directory

Trials / Unknown

UnknownNCT00968292

Stability and 3D Motion Study of an Experimental Prosthetic Foot

Stability & 3D Motion Study of an Experimental Prosthetic Foot

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Tensegrity Prosthetics · Industry
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Accepted

Summary

The investigators are currently verifying early data showing that the K3 Promoter prosthetic foot affects walking efficiency or stability in transtibial, unilateral amputees when compared to their current prostheses. Phase II funds are being used to address these metrics. These studies are important basic research, however, while Tensegrity has the unique opportunity to study amputee gait and movement in the CGMA's state-of-the-art facility the investigators will expand these studies with BRDG-SPAN funding by studying the following metrics: 1. Four Square Step Test (FSST) 2. Amputee Mobility Predictor (AMP) 3. Timed Up and Go Test (TUG) 4. Quality of life (QOL) index (SF-36) 5. Activity-specific Balance Confidence Questionnaire (ABC) 6. 3D motion analysis

Detailed description

The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.

Conditions

Interventions

TypeNameDescription
DEVICEExperimental prosthetics foot (K3 Promoter)The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.

Timeline

Start date
2010-05-01
Primary completion
2010-08-01
Completion
2010-08-01
First posted
2009-08-28
Last updated
2009-08-28

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00968292. Inclusion in this directory is not an endorsement.